Episode 14

Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer

Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.

Next Episode All Episodes Previous Episode

About the Podcast

Show artwork for Breast Cancer Update
Breast Cancer Update
This series bridges the gap between research and patient care by providing on-going access to the perspectives and opinions of national and international breast cancer research leaders.

Listen for free